Health
Drug Compound Targets Weakness in Advanced Prostate Cancer – Technology Networks
A new study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted using the compound thymoquinone.
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene. Led by researchers at Kanazawa University, the study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted. SUCLA2-deficient prostate cancers represent a significant fraction of those resistant to hormone therapy or metastatic, and a new therapeutic option for this disease would have immense benefits for patient…
-
Noosa News11 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
General20 hours agoProductivity summit ends day two with progress on rules changes to boost housing supply
-
General21 hours agoRed tape on chopping block in bid to build homes faster
-
Noosa News23 hours agoGirl charged with attempted murder after foster carer stabbed in Ipswich